Research Article
Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Table 2
General information on adverse events.
| | Categories by patient1 and adverse events (AEs) | Locally advanced (%) | Metastatic (%) | Recurrent (%) | Total (%) |
| | Patients with an adverse event | 18 (78.3) | 27 (67.5) | 4 (100) | 49 (73.1) | | Patients with TRAE | 1 (4.35) | 2 (5.0) | 1 (25) | 4 (5.9) | | Patients with grade 3-4 TRAE | — | 1 (2.5) | — | 1 (1.5) | | Adverse events | 125 (39.2) | 160 (50.2) | 34 (10.7) | 319 (100) | | Treatment-related AE | 11 (8.8) | 14 (8.7) | 1 (2.9) | 26 (8.1) | | Grade 3-4 treatment-related AE | — | 4 (2.5) | — | 4 (1.2) |
|
|
1Subject can be included in more than one category. TRAE: treatment-related adverse events.
|
